Biotech | December 14, 2021
Samsung Biologics expands tie-up with AstraZeneca to include cancer therapy
The company will manufacture a cancer immunotherapy product from 2022
The company will manufacture a cancer immunotherapy product from 2022
Approvals accorded under Production Linked Incentive (PLI) Scheme for promotion of domestic manufacturing of critical Key Starting Materials (KSMs)/ drug intermediates and Active Pharmaceutical Ingredients (APIs
These results demonstrate the potential benefits of heterologous boosting (mix-and-match). The article describing these results have been posted on medRxiv
ALASTIN’s patented, differentiated technology and products are highly synergistic with Galderma’s premium portfolio
Share of government health expenditure in total health expenditure increases to 40.8% (2017-18) from 28.6% (2013-14)
It is estimated that one-third of our country’s population has some form of these disorders
ImmunoACT has a portfolio of CAR-T therapy assets under various development stages for the treatment of multiple autoimmune diseases and oncology indications.
Strides Pharma Science has reported consolidated financial results for the period ended September 30, 2021
Two leaders in science combine complementary best-in-class technologies for biologics manufacturing customers
Dupixent is the only biologic medicine to improve lung function in children aged 6 to 11 years in a randomized Phase 3 trial, supporting potential as a best-in-class option
Subscribe To Our Newsletter & Stay Updated
